Latest News

Key Insights TOWA's estimated fair value is JP¥3,409 based on 2 Stage Free Cash Flow to Equity Current share price of...

Last week, you might have seen that Kewpie Corporation ( TSE:2809 ) released its quarterly result to the market. The...

Mercari, Inc. ( TSE:4385 ) announced strong profits, but the stock was stagnant. Our analysis suggests that this might...

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Typically...

The market was pleased with the recent earnings report from Tess Holdings Co.,Ltd. ( TSE:5074 ), despite the profit...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

We wouldn't blame Alkane Resources Ltd ( ASX:ALK ) shareholders if they were a little worried about the fact that Ian...

If you are watching Proximus and wondering what to do next, you are not alone. With a share price that just closed at 7.3, investors have every reason to re-examine the stock’s direction. Over the last week, Proximus slipped by 0.9%, but that comes after a solid 1.0% climb in the last month and an impressive year-to-date surge of 43.3%. Looking back over the past year, the stock is up 17.0%, a stark contrast to where things stood five years ago with a drop of 37.4% over that period. What is...

Eurofins-Cerep (ENXTPA:ALECR) reported net profit margins of 17.7%, a slight uptick from last year’s 17.3%. The company has delivered average annual earnings growth of 3.2% over the past five years, but recent results show negative earnings growth year over year, making short-term comparisons less meaningful for now. Investors are likely to focus on the attractive valuation, as the stock trades at a Price-To-Earnings Ratio of 12.8x, which is well below both the peer group (60.7x) and the...

Deciding what to do with ERG stock right now might feel a bit like standing at a crossroads, wondering which path holds the better payoff. On one hand, the stock closed recently at 21.98 and has enjoyed a decent pick-me-up over the past week and month, rising 5.2% and 7.1% respectively. Year to date, ERG is up 8.1%. However, taking a step back, the view changes. Over the past year, the stock has slipped 2.1%. Looking further out, the 3-year return paints a cautious picture, dropping by 11.9%...

If you have been watching ThredUp lately, you know it is one of those rare stocks that keeps drawing your attention. Whether you are holding after that massive 1-year surge or you are still weighing your next move, there is a lot to unpack. ThredUp has soared an eye-catching 1111.0% over the last year, with a staggering 568.8% gain year-to-date. Even after a recent 30-day dip of -10.7%, it has still notched a respectable 2.4% gain in the past week. This reminds investors that volatility can...

If you are wondering whether to stick with Nomura Holdings or add it to your watchlist, you are not alone. Investors all over the globe are sizing up what is turning out to be one of Japan’s most interesting financial stories this year. The stock may have dropped 6.6% over the past week, but do not let short-term noise drown out the bigger narrative. Nomura is up a massive 42.1% over the last 12 months and an eye-watering 166.5% over the past five years. That is not just a recovery, but a...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Foley Wines...

Ovid Therapeutics recently announced positive topline results from its Phase 1 study of OV329, a next-generation GABA-aminotransferase inhibitor targeting drug-resistant epilepsies, demonstrating significant GABAergic inhibition and strong safety outcomes in 68 healthy volunteers. This clinical milestone signals potential advancement in the treatment of drug-resistant epilepsies and attracted new institutional investors through a substantial private placement. We'll explore how OV329’s early...

Thinking about what to do with Van Lanschot Kempen? You are not alone, especially as this stock has caught the eye of investors with a return of 4.4% over the past week and a strong 16.8% gain so far this year. If you look further back, the one-year return comes in at 32.5%, and over three years, a massive 261.9%. Clearly, something is driving this sustained momentum, which is making investors wonder whether now is the time to get on board or if all the growth has already been priced in. Some...

If you are sitting on the fence about Telefónica Deutschland Holding, you are not alone. With a share price that has slid by 1.8% in the last week and is down 6.8% over the past year, investors are understandably weighing their options. It is easy to let short-term moves sway your decision, but sometimes these drops mean opportunity, not just risk. Recently, broader market shifts and sector-specific developments have altered perceptions of telecom stocks in Germany. Telefónica Deutschland has...

Trying to figure out what to do with Traton stock? You are not alone. Whether you are wondering if it is time to buy more, hold tight, or maybe look elsewhere, recent moves in Traton’s share price have definitely caught investors’ eyes. Over just the last week, shares nudged up by 2.0%, after a somewhat bumpy ride: down 6.1% in the last month, but only slightly negative for the year to date. Longer-term, things look even more interesting. Traton is up 4.1% over the past year and has soared an...

On September 24, 2025, Zura Bio Limited adopted an Executive Severance Benefit Plan, outlining compensation for executives if terminated without cause or upon resignation for good reason, especially in the context of a change in control. This move comes as the company, which reported having US$154 million in cash with a reported runway of 3.5 years as of June 2025, faces scrutiny over its increasing cash burn and potential funding needs. We'll examine how concerns around Zura Bio's executive...

Guangzhou Automobile Group (SEHK:2238) shares have caught the eye of investors recently, especially after their one-year total return reached 6% and quarterly returns jumped 13%. Let’s take a closer look at what is driving this performance. See our latest analysis for Guangzhou Automobile Group. The recent climb in Guangzhou Automobile Group's share price, capped by a strong 13% rise over the past quarter, signals growing optimism about its near-term prospects. Even though its one-year total...

centrotherm international (DB:CTNK) reported a net profit margin of 10.8%, down from 12.3% last year, with earnings growing 38.8% year-over-year but trailing its stellar five-year annualized growth of 54.6%. Shares currently trade at €6, which is significantly below the estimated fair value of €40.75 and at a low Price-To-Earnings ratio of 4.9x, far under industry and peer averages. These numbers highlight strong ongoing profitability and an eye-catching value proposition, even though the...

If you’ve been scanning the markets wondering whether now is the right time to buy, hold, or move on from Alexander & Baldwin, you’re not alone. This stock can puzzle even seasoned investors, especially after a rollercoaster of performance. Over the past five years, Alexander & Baldwin’s price has soared nearly 80%, which is impressive for a real estate-focused name. Those who’ve sat tight since 2021 are still up over 22% despite the flat year-over-year returns, and a slight dip of -0.4% in...

White Gold Corp. recently announced a brokered private placement to raise funds for exploration, offering premium flow-through units, flow-through shares, and standard units, each with associated pricing and warrant terms, and subject to regulatory approval. This fundraising effort follows an updated mineral resource estimate showing a 44% increase in indicated gold ounces, enhancing the company's potential for further economic assessments. We'll explore how the significant increase in...

Trying to figure out whether Morinaga&Co is a good buy right now? You are definitely not alone. With so many moving parts in today's markets, it's easy to get caught up in short-term dips and surges. Morinaga&Co’s stock has slid by 3.8% in the last week and is down 4.9% over the past month. Year to date, shares are off 5.2%, adding up to a 7.3% dip over the last twelve months. However, if you take a step back, there is an interesting twist: over the last 3 and 5 years, the stock posted...